Improve your value proposition for today and tomorrow.

The FDA’s recent draft guidance on medical devices with software will require companies’ complete attention.

Scalability should be on top of the list of strategic topics regardless of a company’s size or stage.

The FTC and the EU’s scrutiny of healthcare/life sciences M&A plays a vital role in shaping the industry’s core markets.

In a world where Digital Health and AI are buzzwords: what happened to medical device manufacturing? Is it still a positive business to be in? What’s the long-term outlook? What’s the geopolitical climate for this type of manufacturing? Should I continue to invest and grow?

Major MedTech corporations often engage in acquisitions to drive their growth and market dominance.

Is Europe’s regulatory burden a loss for the EU and a gain for the U.S.?

Blood-based molecular cancer test delivers accuracy and specificity levels unsurpassed by other diagnostic methods.

Dave and Florence review the M&A activity for the top 12 highest-grossing medtech companies since 2022 in this months MPO column.

With potential acquirers contacting us every week seeking a company in one of the categories, it’s clear the medical M&A market is still highly active in 2023! For further validation, our frequent flyer miles this year are higher than ever.

Ortoma to present groundbreaking 2D-3D technology for knee and hip joints at the annual ISTA congress in New York 2023.

Will a computer buy your MedTech business or write this article? Contemplating the impact of machine learning (ML) and artificial intelligence (AI) on MedTech & M&A.

Congratulations to MPO on its 20th anniversary! In this article we discuss how M&A will clearly continue to play a key role in the MedTech sector’s future.

Congratulations to our client Ortoma, who following a clinical evaluation of their OTS™ Hip solution, are now working with Johnson & Johnson K.K. to initiate a broad distribution of OTS™ Hip in Japan. 

In the May 2023 edition of Today’s Medical Development Magazine our team discusses reshoring and nearshoring in China and why MedTech players shouldn’t rely solely on production there.